Molecular Breast Imaging

Comparison of RCC mammogram and RCC BSGI

 

Breast-Specific Gamma Imaging (BSGI) is a molecular breast imaging technique that is advancing the early detection of breast cancer, especially in difficult-to-diagnose patients. As an adjunct to mammography, BSGI utilizes the Dilon 6800® Gamma Camera to help physicians see the breast more clearly and differentiate between benign from malignant tissue.

The Procedure

With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells. Therefore, malignant cells generally appear as “dark spots” on the BSGI image.

BSGI has very high sensitivity for identifying earlier stage cancers — as small as 1 mm as shown in clinical studies; and with a Negative Predictive Value (NPV) comparable to MRI.

The Dilon 6800® Gamma Camera is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. BSGI with the Dilon 6800 system can help physicians:
  • identify lesions independent of tissue density
  • duplicate standard mammographic views
  • discover early stage cancers

Dilon 6800, small field-of-view-gamma camera (anatomically specific)


BSGI aids in the effective management of suspicious and difficult-to-interpret breast cases.

More specifically, BSGI with the Dilon 6800:
  • significantly aids in the differentiation of benign and malignant tissue
  • results in lower false positive rates with fewer patient restrictions than MRI
  • is sensitive to small non-palpable lesions
  • provides very high sensitivity for detecting DCIS and lobular carcinomas
  • helps evaluate the need and localize areas of interest for biopsy
  • aids in determining the extent of disease
  • can help monitor neoadjuvant tumor therapy
right_image
Print this page
Send this page to a friend
bottom